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Abstract
Background: Cystic fibrosis (CF) is an inherited, rare autosomal recessive disease that results in chronically
debilitating morbidities and high premature mortality. We evaluated how ivacaftor treatment affected CF
symptoms, functioning, and well-being, as measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a
widely-used patient-reported outcome (PRO) measure.
Methods: STRIVE, a double-blind, placebo-controlled randomized trial, evaluated ivacaftor (150 mg) in CF
patients aged 12+ with the G551D-CFTR mutation for 48 weeks. Treatment effect analysis used a mixed-effects
repeated measures model. Treatment benefit analyses applied the cumulative distribution function and a categorical
analysis of change scores (“improvement,” “no change,” or “decline”). Content-based interpretation examined treatment
effect on specific item responses.
Results: Data from 152 patients with a baseline CFQ-R assessment were analyzed. The treatment effect analysis favored
treatment with ivacaftor over placebo on the Body Image, Eating, Health Perceptions, Physical Functioning, Respiratory,
Social Functioning, Treatment Burden, and Vitality scales. Findings were supported by the analysis of categorical
change. On all CFQ-R scales, the percentage of patients who improved was greater for ivacaftor. In the content-based
analysis, the treatment benefit was characterized by better scores across a broad range of domains.
Conclusions: Results illustrate broad benefits of ivacaftor treatment across many domains: respiratory symptoms, physical
and social functioning, health perceptions, and vitality, as measured by the CFQ-R. The breadth of improvements reflects
the systemic mechanism of action of ivacaftor compared to other therapies. Findings support the patient-reported value
of ivacaftor treatment in this patient population.
Trial Registration: ClinicalTrials.gov NCT00909532
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Background
Cystic Fibrosis (CF) is a rare, autosomal recessive
disease affecting multiple organs, including the
lungs, pancreas, sweat glands, and intestinal, biliary
and reproductive tracts [1]. CF is caused by defects
in the CF transmembrane conductance regulatory
(CFTR) protein resulting from mutations in the
CFTR gene. Some CFTR mutations produce CFTR
protein channels that have defective gating (reduced
channel open probability), resulting in little to no
net chloride ion transport [2–4]. Patients with CF
who have at least one CFTR mutation of this type
are at high risk for early lung function decline and
progression of other disease manifestations. The
most prevalent CFTR mutation that predominantly
affects CFTR channel open probability is G551D,* Correspondence: mbayliss@qualitymetric.com3Optum, 24 Albion Road, Bldg 400, Lincoln, RI 02854, USA
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which is found in approximately 4 % of patients with
CF in the United States [5].
Ivacaftor (Kalydeco®) was approved by the FDA in
January 2012 for the treatment of CF in patients 6 years
of age and older who have the G551D mutation on at
least one CFTR allele. The approval was expanded in the
US in February 2014 and December 2014 to include 9
additional mutations [6]. All of the currently indicated
mutations affect CFTR channel open probability as their
primary molecular dysfunction.
The Phase 3 clinical program for ivacaftor was designed
to assess the efficacy and safety of ivacaftor treatment in
patients with at least one of the specified CFTR mutations.
Treatment-related changes in patient-reported outcomes
(PROs) were evaluated and have been previously reported
for children (ENVISION study), and adolescents and
adults (STRIVE study) [7, 8] with at least one G551D-
CFTR mutation.
Developers of drugs are expected to provide direct
evidence of the treatment benefit as experienced by
patients. Providers, regulators, and payers seek infor-
mation about how patients feel and function in daily
life, with evidence from pivotal trials implementing
well-defined and reliable assessments. To that end,
we expand on data previously reported that show
the impact of CF and its treatment on how patients
feel and function in everyday life.
The objective of this study was to evaluate the
treatment effects of ivacaftor on patient-reported
symptoms and health-related quality of life (HRQoL)
as reported by patients with CF 12 years of age and
older with the G551D-CFTR mutation participating
in the STRIVE study. The specific aim was to interpret
treatment benefit using innovative analyses of PRO data
covering a broad range of HRQoL domains and CF symp-
toms, specifically: 1) mean changes in Cystic Fibrosis
Questionnaire-Revised (CFQ-R) scale scores from baseline
through 48 weeks of treatment; 2) patterns of treatment
response using empirically-defined categories of change;
and 3) examination of treatment using responses to salient
items of the CFQ-R that characterized disease impact.
Methods
Data source
STRIVE was a randomized, double-blind, placebo-
controlled study evaluating ivacaftor, a CFTR potentiator,
in subjects 12 years of age or older with CF and at least
one G551D-CFTR mutation. Patients were randomly
assigned in a 1:1 ratio to receive 150 mg of ivacaftor or
placebo every 12 h for 48 weeks. Throughout the study,
all patients continued to take their pre-study medica-
tions (with the exception of hypertonic saline). The pri-
mary endpoint was the estimated mean absolute change
from baseline through week 24 in the percent predicted
forced expiratory volume in 1 s (FEV1 % predicted). Sec-
ondary endpoints included the change from baseline
through week 48 in the FEV1 % predicted, time to first
pulmonary exacerbation, change in body weight, change
in concentration of sweat chloride, as well as patient-
reported scores from the CFQ-R Respiratory Symptoms
Scale [9–11].
The study included a 2-week screening period, a 2-week
run-in period, and a 48-week treatment period. Efficacy
and safety findings from this study have been previously
reported [9].
Cystic fibrosis questionnaire-revised
The CFQ-R was the first disease-specific PRO instrument
developed for use by patients with CF and their caregivers
[12]. The original CFQ was developed from qualitative and
quantitative studies which included a conceptual frame-
work, interviews with patients, parents, and health care
professionals, cognitive testing, and psychometric evalu-
ation [10, 12–14]. Modifications were subsequently made
to the instrument leading to the current revised version,
which has been identified as a widely used PRO measure
for CF [15–17].
Three versions of the CFQ-R are available: a self-
completed Teen/Adult version for patients with CF aged
14 and older, a Child version for children aged 6–13 years
(self-report for ages 12–13 and interviewer-administered
for ages 6–11), and a proxy-completed Parent/Caregiver
version. The Teen/Adult and Parent/Caregiver versions
include the following scales: Body Image, Digestive Symp-
toms, Eating Problems, Emotional Functioning, Health
Perceptions, Physical Functioning, Respiratory Symptoms,
Role Functioning, Social Functioning, Treatment Burden,
Vitality, and Weight. The Child version does not include
Health Perceptions, Role Functioning, Vitality, and
Weight. Items included in each scale of the CFQ-R are
summed and standardized to a 0–100 scale, with higher
scores indicating better outcomes or fewer symptoms
from the patient perspective.
In the STRIVE study, the CFQ-R was administered at
the beginning of the run-in period, baseline, day 15,
week 8, and every 8 weeks thereafter, up to week 48. Pa-
tients aged 14 and older completed the Teen/Adult ver-
sion while those aged 12 and 13 at baseline completed
the Child version. Parents of children aged 12 and 13 at
baseline also completed the Parent/Caregiver version.
This analysis included pooled data from the two self-
completed Teen/Adult and Child versions (data from
the Parent/Caregiver version were not included).
Analyses
Treatment-related changes in CFQ-R domains
For each scale of the CFQ-R, mean changes from baseline
through week 48 were evaluated by treatment group using
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a mixed-effects model for repeated measures [18] with ab-
solute change from baseline as the dependent variable, fixed
effects for study visit and treatment group, and adjustment
for continuous baseline values of age, FEV1 % predicted,
and baseline scale score, using an unstructured covariance
matrix. Treatment effect was calculated as the difference in
mean change from baseline between the ivacaftor and pla-
cebo groups. A p-value of <0.05 was employed to assess
statistical significance.
In addition to evaluating treatment benefit as mean
change from baseline, the current analyses also in-
cluded evaluating treatment group differences in
terms of the percentage of patients reporting various
levels of change across the different CFQ-R domains.
First, to evaluate treatment group differences across
the entire range of observed change, we used a
method based on the cumulative distribution func-
tion (CDF). The CDF of change scores presents the
proportion of patients who experienced an improve-
ment or decrement at or below a specific value [19].
When presented separately by treatment group, CDF
plots illustrate the separation between groups at each
threshold of change. For evaluating treatment response,
CDFs are most easily interpreted when the y-axis is re-
versed to show the proportion of patients with a score
change > |X|, an approach known as cumulative re-
sponse curves (CRCs) [20]. We evaluated the CRCs for
change from baseline to week 48 by CFQ-R scale, by
treatment group. Statistical significance was assessed
using the two-sample Kolmogorov-Smirnov test.
In addition to the CRC analysis, we used a
distribution-based methodology [21] to establish thresh-
old values that help interpret the magnitude of change
observed in HRQoL scores. One-half standard deviation
(SD) of the change from beginning to end of the 2-week
run-in period (2 weeks prior to study drug initiation)
was used as a threshold value [22] to identify minimal
important change. The direction and magnitude of score
changes were used to analyze treatment response.
Positive or negative changes from baseline to week 48
exceeding (in absolute value) the threshold were consid-
ered “improvements” or “declines”, respectively. Change
scores smaller (in absolute value) than the threshold
value were considered “no change”. The Chi-square test
was used to assess statistical significance of treatment
group differences.
Sensitivity analyses were conducted using the standard
error of measurement (SEM). The SEM reflects the
measurement precision and the amount of random vari-
ation from repeated assessments. One SEM has been
proposed as a measure of minimal clinically important
difference (MCID) and was used to identify “improve-
ment”, “no change”, or “decline” [23], with the Chi-
square test for assessment of group differences. The
SEM was evaluated as SEM ¼ SDΔ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−ICCð Þp , where
SDΔ is the SD of change scores from the run-in period
and the ICC is the intraclass correlation coefficient, a
measure of reliability related to the repeated administra-
tion of the same test under the assumption that substan-
tial change in the concept of interest has not occurred.
Content-based interpretation of treatment effects
These analyses examined the impact of treatment on re-
sponses to specific “sentinel” CFQ-R items empirically
selected to represent each scale. Polyserial or Spearman
[24] correlations between change in each item and
change in its scale were calculated. The item with the
strongest association with its scale change score was
identified as the sentinel item. Response options for each
sentinel item were collapsed into “none” vs. “any” im-
pairment. The change in percent of patients with no im-
pairment was evaluated by treatment group at baseline
and week 48.
Ethics
The STRIVE clinical trial (“A Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Parallel-Group Study
to Evaluate the Efficacy and Safety of VX-770 in Subjects
with Cystic Fibrosis and the G551D Mutation”) protocol
was reviewed and approved by the institutional review
board at each participating center, and each subject pro-
vided written informed consent or written or oral assent.
Results and discussion
Characteristics of study sample
The STRIVE study randomized 167 subjects to two
treatment arms. Of these, 161 subjects subsequently re-
ceived at least one dose (intention-to-treat analysis).
This study sample contained the 152 patients who com-
pleted a baseline CFQ-R assessment. The two treatment
groups were similar in terms of gender (53.0 % female)
and mean age (25.7 years). Most patients were 18 years
of age or older (77.6 %). At baseline, the treatment
groups also were similar in average FEV1 % predicted
(64.6 %), mean sweat chloride (100.4 mmol/L), height
(167 cm), body weight (78.9 kg), and body mass index
(BMI) (21.9 kg/m2).
Treatment-related changes in CFQ-R scales
Figure 1 shows the observed mean and standard
error of the change from baseline at each study visit,
by scale and treatment group. Mean change on the
Body Image, Eating Problems, Health Perceptions,
Physical Functioning, Respiratory Symptoms, Social
Functioning, Treatment Burden, and Vitality scales
was consistently higher for ivacaftor vs. placebo.
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Favorable effects of ivacaftor were observed within
the first 2 months of treatment initiation.
Table 1 presents baseline score, mean change from base-
line through week 48, and treatment effects (difference be-
tween treatment groups in mean change) by CFQ-R scale
and treatment group. For seven of the twelve CFQ-R
scales, the mean post-baseline change was statistically sig-
nificant, after adjustment for age, FEV1 % predicted, and
baseline CFQ-R scale score. The largest treatment effect
was found on the Respiratory Symptoms scale with a
Fig. 1 Change from baseline in CFQ-R scores for each visit by treatment group (observed data). SE = standard error; means and standard error
are unadjusted
Table 1 CFQ-R adjusted change scores from baseline through week 48 by treatment group
CFQ-R Scale Placebo Ivacaftor
(N = 70b) (N = 80b)
Baseline Change Baseline Change Treatment effect p-valuea
Body Image 80.3 −1.2 81.0 1.5 2.7 0.086
Digestive Symptoms 85.4 0.4 85.2 0.8 0.5 0.732
Eating Problems 91.9 −1.1 91.8 2.2 3.3 0.002
Emotional Functioning 83.6 −1.4 86.0 0.7 2.1 0.096
Health Perceptions 71.7 −3.6 72.1 4.0 7.6 <0.001
Physical Functioning 80.2 −1.7 76.1 2.7 4.4 0.006
Respiratory Symptoms 68.5c −2.7 70.2 5.9 8.6 <0.001
Role Functioning 85.9 0.1 86.3 −0.5 −0.6 0.651
Social Functioning 71.9 −1.0 72.1 3.3 4.3 0.003
Treatment Burden 65.7 1.0 64.5 4.3 3.3 0.042
Vitality 64.7 −2.8 64.3 2.7 5.5 0.002
Weight 78.1 1.7 79.0 6.9 5.3 0.053
Health Perceptions, Role Functioning, Vitality and Weight are not included in the Child self-report version of the CFQ-R; results for these scales are based on the
Teen/Adult version only (N = 64 for placebo and N = 76 for Ivacaftor)
aP-value for overall post-baseline treatment effect, estimated using a mixed-effect model for repeated measures with fixed effects for study visit, treatment group,
and adjustment for continuous baseline values of age, percent predicted FEV1 and domain score
bAnalysis sample includes patients with a baseline assessment and at least one post-baseline assessment
cn = 71
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mean improvement of 5.9 points observed among
patients receiving ivacaftor, exceeding the MCID
value of 4 points, vs. a mean decline of 2.7 points
among those receiving placebo (treatment effect of
8.6 points, P < 0.001) [12].
Figure 2 presents CRCs of change scores from baseline
to week 48, by treatment group. For nearly all CFQ-R
scales, lower cumulative change scores (worse outcomes)
were seen for the placebo group, indicated by the dashed
curve for the placebo group appearing to the left of the
solid curve for ivacaftor. These findings suggest that the
proportion of subjects who exceeded a particular level of
change (better outcomes) was higher in the ivacaftor
than placebo group. Differences between treatment
groups (favoring ivacaftor) were greatest for Respiratory
Symptoms (p < 0.001), Physical Functioning (p = 0.002),
Health Perceptions (p = 0.019), and Vitality (p = 0.030).
Using illustrative values of 5 and 10 points, the percentage
of patients with change scores greater than 5 on the Re-
spiratory Symptoms scale was 59 % for ivacaftor vs. 27 %
in the placebo group. For changes greater than 10 points,
percentages were 47 and 11 % for ivacaftor and placebo,
respectively. For change scores of 5 and 10 points on
Physical Functioning, percentages of ivacaftor-treated pa-
tients with improvement were 36 and 23 %, respectively,
compared to 13 and 8 % in the placebo group.
Figure 3 presents the percentage of patients who expe-
rienced “improvement”, “no change”, or “decline” after
48 weeks of treatment with either ivacaftor or placebo,
according to our change threshold of 0.5 SD. Differences
favoring ivacaftor were observed for Respiratory Symp-
toms (P < 0.001), Social Functioning (P = 0.026), Vitality
(P = 0.006), Treatment Burden (P = 0.016), Health Per-
ceptions (P = 0.003), Physical Functioning (P < 0.001),
Eating Problems (P = 0.015), and Weight (P = 0.015).
Results were similar under the 1 SEM criterion (see
Additional file 1: Tables S1 and Additional file 2: Table S2).
Content-based interpretation of treatment effects
Table 2 shows the sentinel items by CFQ-R scale
and the baseline percentage of patients reporting
“no impairment”.
The proportion of patients treated with ivacaftor who
showed “no impairment” generally increased between
baseline and week 48 and decreased among patients
treated with placebo (data not shown). The items with at
least 10 % separation between ivacaftor and placebo at
week 48 were: “feel healthy” (17.5 % separation), “walk-
ing as fast as others” (15.1 %), “coughing” (14.1 %), “going
out with friends” (14.1 %), “trouble gaining weight”
(14.0 %), “force myself to eat” (13.5 %), and “treatment
makes life more difficult” (12.5 %).
Fig. 2 Cumulative response curves for CFQ-R scales by treatment group. P-values from the Kolmogorov-Smirnov two-sample test for equality of
cumulative distribution functions
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Fig. 3 Analysis of categorical change from baseline to week 48 by CFQ-R scale and treatment group. *p-value < 0.05. from chi-square
test for differences between treatment groups in the percentage of “improvement”, “no change” and “decline” patients
Table 2 Percentage of patients with “no impairment” in representative CFQ-R items at baseline and 48 weeks
Representative items % No Impairment at
baseline (pooled)CFQ-R scale Teen-adult version/Child version Response optiona Corr.b with domain change score
Body image Look different from others Very false/Not at all true 0.82 60.0
Digestive symptoms Problems with gas/stomach hurt Never 0.85c 48.1
Eating problems Force myself to eat/pushed to eat Very false/Never 0.82c 77.7
Emotional functioning Felt sad/worried Never 0.79 71.1
Health perceptions Feel healthy Very true 0.86 32.5
Physical functioning Walking as fast as others No difficulty 0.85 65.9
Respiratory symptoms Coughing Not at all/Never 0.85 3.7
Role functioning Running errands out of the house Never 0.85 41.0
Social functioning Comfortable going out/got
together with friends
Very true 0.66 59.2
Treatment burden Tx makes life more difficult/Tx
bothered you
Not at all/Not at all true 0.78 25.1
Vitality Felt exhausted/grouchy Never 0.81 47.4
Weightd Trouble gaining weight Not at all e 62.0
aIdentified to represent patient report of no impairment
bPolyserial correlation unless otherwise noted
cSpearman correlation
dSingle item scale
eNot applicable for single item scales
Pooled = ivacaftor and placebo
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Figure 4 presents the change in percentage with “no im-
pairment” from baseline to week 48 by treatment group. As
before, the percentage with “no impairment” in-
creased with ivacaftor and decreased with placebo
between baseline and week 48 for most items, eg,
“walking as fast as others”(+13.7 vs. −10.7 %, re-
spectively), “feel healthy” (+10.2 vs. −4.5 %), “running
errands out of the house” (+18.0 vs. −1.2 %), “going
out with friends” (+11.2 vs. −0.7 %), [never feeling]
“bothered by treatment” (+15.7 vs. −1.0 %).
Conclusions
Our analyses provide empirical data describing and
quantifying the benefits of ivacaftor treatment in pa-
tients aged 12 years and older with CF and the
G551D-CFTR mutation.
In the STRIVE study, early and sustained treatment ef-
fects from ivacaftor were observed through week 48 on the
CFQ-R Respiratory Symptom scale. The magnitude and
significance of the improvements in Respiratory Symptoms
was consistently observed across the analyses in line with
improvements in % predicted FEV1 in the study population.
Of interest, sustained improvements were also observed on
other scales of the CFQ-R, including Physical Functioning,
Social Functioning, Eating Problems, Treatment Burden,
Health Perceptions, and Vitality. Trends also were favorable
for ivacaftor-treated patients on the Body Image, Digestive
Symptoms, Role Functioning, and Emotional Functioning
scales, but their magnitude was smaller and failed to reach
statistical significance.
These positive changes across multiple CFQ-R
scales are supported by findings from categorical
change analyses. Using change scores classified into
“improvement”, “no change”, or “decline”, the treat-
ment effects favoring ivacaftor over placebo became
even more apparent. On all 12 CFQ-R scales, the
percentage who improved by week 48 was greater
for ivacaftor-treated patients. Further, the percentage
who declined was greater for placebo-treated pa-
tients, although differences across the three categor-
ies of change were not statistically significant for
Role Functioning, Body Image, Emotional Function-
ing, and Digestive Symptoms. For the Respiratory
Symptoms and Physical Functioning scales, the iva-
caftor group included at least five times more pa-
tients with improvements compared to placebo. For
the Social Functioning, Vitality, Treatment Burden,
and Role Functioning scales, the ivacaftor group in-
cluded three to five times more patients with im-
provements compared to placebo. Worsening scores
through week 48 were more prevalent among pa-
tients on placebo. Of particular interest are the
Fig. 4 Change in the percentage of patients with no impairment after 48 weeks of treatment
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Weight scores, with a three-fold difference between
ivacaftor and placebo in the percentage of patients
who declined during the study (9 vs. 28 %).
The content-based analysis of sentinel items-showed
that ivacaftor led to improvements in a broad range of
functional outcomes, including the respiratory, nutri-
tional, physical, social, and treatment-related domains.
Although several trial-based publications have docu-
mented treatment benefits using the CFQ-R, they have
focused on selected scales: Respiratory Symptoms, Phys-
ical Functioning, and Vitality [25–30]. Additional data,
particularly from observational studies, would provide
needed real-world evidence to complement trial-based
data on the patient-reported benefits associated with iva-
caftor treatment. In the PERSIST open-label extension
study sample, including 75 % (n = 144) of the STRIVE
sample, the effect of ivacaftor on the CFQ-R Respiratory
Symptoms scale was maintained over an additional
96 weeks of treatment [31]. In an observational study of
ivacaftor (US GOAL), clinically meaningful and statisti-
cally significant gains (7.4 points, p < 0.0001) were ob-
served in the Respiratory Symptoms scale after
6 months of treatment [32].
Clinicians, patients, and other stakeholders will benefit
from understanding the impact of ivacaftor treatment on
patients with selected CF mutations using a patient-
centered point-of-view. We have presented direct evidence
of therapy effects, extending the interpretation of treatment
benefit beyond the previously reported clinical markers.
These results complement the clinical results, providing
evidence of how patients feel and function in daily life. Our
findings suggest that ivacaftor treatment led to significant
improvements that were substantial, sustained over
48 weeks, and spanned a wide range of symptoms, func-
tioning, and well-being in patients with the G551D-CFTR
mutation in the STRIVE study.
Results from the STRIVE study illustrate broad bene-
fits of ivacaftor treatment across highly salient aspects of
HRQoL: respiratory symptoms, physical and social func-
tioning, health perceptions, and vitality as measured by
the CFQ-R in patients with CF 12 years of age and older
with the G551D-CFTR mutation. The breadth of im-
provements reflects the systemic mechanism of action of
ivacaftor compared to other (symptomatic) therapies.
Our results are supportive of the patient-reported value
of ivacaftor treatment in this patient population.
Limitations: The analyses reported here are post-
hoc in nature (not pre-specified). Although an MCID
has been established for the Respiratory Symptoms
scale [12], no such benchmarks for interpretation of
change exist for the remaining CFQ-R scales. Fur-
ther, we used distribution-based methods to identify
thresholds of change [21] because use of an anchor-
based method was not possible using these data. The
STRIVE study included only patients with the
G551D-CFTR mutation. As noted, our findings are
based on results of a clinical trial and the magnitude
of treatment effects of ivacaftor on patient-reported
outcomes may differ in actual clinical practice.
Additional files
Additional file 1: Categorical change from baseline-week 48 by
CFQ-R scale and treatment group: 0.5 SD threshold.
Additional file 2: Categorical change from baseline-week 48 by
CFQ-R scale and treatment group: SEM threshold.
Competing interests
Author AQ has received Investigator-initiated grants from Vertex and Gilead
Sciences and consulting income from AbbVie, Vertex, and Gilead. Authors ES,
BC, and MV-L are employees of Vertex Pharmaceuticals Incorporated and
may own stock or stock options in that company. Authors RR-B and MB are
employed by Optum, which has been contracted by Vertex to carry out research
activities related to this presentation; these authors have no conflicts of interest to
disclose. Author IS-G as Principal Investigator received grant supports for conduct
of clinical trials from Vertex Pharmaceuticals Incorporated. The CFQ-R is free to use
for clinical purposes once the electronic copyright form is submitted.
Authors’ contributions
Qualifications for authorship have been met as follows: study conception
and design (AQ, ES, MV-L, BC, MB, RR-B); acquisition of data (AQ, ES, MV-L,
BC, IS-G); analysis and interpretation of data (AQ, ES, MV-L, BC, MB, R-RB);
drafting of manuscript (MV-L, MB, and RR-B); and critical revision (all authors).
All authors read and approved the final manuscript.
Acknowledgements
We extend our deepest appreciation to the adolescents and adults with CF
who participated in the STRIVE study. Medical writing assistance was
provided by Caroline Jennermann of Optum. Editorial input to earlier
versions of the manuscript was provided by Cecile LeCamus MD, Barry
Lubarsky PhD, and Jeff Wagener MD. The STRIVE clinical trial was funded and
conducted by Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
This post hoc analysis of data from STRIVE was also funded by Vertex
Pharmaceuticals; however, the conception and design of these analyses and
the interpretation of results was guided by all authors, as described above in
“Authors’ Contributions”. Martha Bayliss is the guarantor of this paper.
Author details
1Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd,
Coral Gables, FL 33146, USA. 2Vertex Pharmaceuticals Incorporated, 50
Northern Avenue, Boston, MA 02210, USA. 3Optum, 24 Albion Road, Bldg
400, Lincoln, RI 02854, USA. 4Hopital Necker Enfants Malades, Universite Paris
Sorbonne, 149 Rue de Sèvres, Paris 75015, France.
Received: 10 February 2015 Accepted: 23 June 2015
References
1. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and
therapy. Annu Rev Med. 2007;58:157–70.
2. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, et al. Ivacaftor
potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros.
2012;11:237–45.
3. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, et al. Mutations
in the cystic fibrosis transmembrane regulator gene and in vivo
transepithelial potentials. Am J Respir Crit Care Med. 2006;174:787–94.
4. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect
of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
N Engl J Med. 2010;363:1991–2003.
5. Cystic Fibrosis Foundation Patient Registry. 2012 Annual Data Report. Cystic
Fibrosis Foundation. 2012. http://www.cff.org/UploadedFiles/research/
ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf.
Quittner et al. Health and Quality of Life Outcomes  (2015) 13:93 Page 8 of 9
6. KALYDECO® Prescribing Information. Vertex Pharmaceuticals, Inc. 2014.
http://pi.vrtx.com/files/uspi_ivacaftor.pdf.
7. Quittner AL, Ramsey B, Dong Q, Yen K, Elborn JS. Patient-reported outcomes
in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR
mutation. J Cyst Fibros. 2012;11 Suppl 1:S67.
8. Quittner AL, Ramsey B, Dong Q, Yen K, Elborn JS. Patient-reported outcomes
in Phase 3 trials of ivacaftor in patients with CF who have the G551D-CFTR
mutation. Pediatr Pulmonol. 2012;47 Suppl 35:297.
9. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
N Engl J Med. 2011;365:1663–72.
10. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DL, Yegin A, et al.
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a
national sample. Qual Life Res. 2012;21:1267–78.
11. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB.
Determination of the minimally clinically important difference scores
for the Cystic Fibrosis Questionnaire-Revised respiratory symptom
scale in two populations of patients with cystic fibrosis and chronic
Pseudomonas aeruginosa airway infection. Chest. 2009;135:1610–8.
12. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development
and validation of the cystic fibrosis questionnaire in the United
States: a health-related quality-of-life measure for cystic fibrosis. Chest.
2005;128:2347–54.
13. Henry B, Aussage P, Grosskopf C, Launois R. Constructing a disease-specific
quality of life questionnaire for children and adults with cystic fibrosis.
Isr J Med Sci. 1996;32(Suppl):S181.
14. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic
Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and
adult patients. Qual Life Res. 2003;12:63–76.
15. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am
Thorac Soc. 2007;4:378–86.
16. Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS.
Evidence-based assessment of health-related quality of life and functional
impairment in pediatric psychology. J Pediatr Pscyhol. 2008;33:983–96.
17. Committee for Medicinal Products for Human Use (CHMP). Guideline on the
clinical development of medicinal products for the treatment of cystic
fibrosis. European Medicines Agency. 2010. http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2009/12/
WC500017055.pdf. Accessed 21 Apr 2014.
18. Siddiqui O, Hung HM, O’Neill R. MMRM vs. LOCF: a comprehensive
comparison based on simulation study and 25 NDA datasets. J Biopharm
Stat. 2009;19:227–46.
19. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting
patient-reported outcome results: U.S. FDA guidance and emerging
methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163–9.
20. Cappelleri JC, Zou KH, Bushmakin AG, Carlsson MO, Symonds T.
Cumulative response curves to enhance interpretation of treatment
differences on the self-esteem and relationship questionnaire for men
with erectile dysfunction. BJU Int. 2013;111:E115–20.
21. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for
determining responsiveness and minimally important differences for
patient-reported outcomes. J Clin Epidemiol. 2008;61:102–9.
22. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of
life in clinical trials. CMAJ. 1986;134:889–95.
23. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change
in health-related quality of life. J Clin Epidemiol. 2003;56:395–407.
24. Cox NR. Estimation of the correlation between a continuous and a discrete
variable. Biometrics. 1974;30:171–8.
25. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ,
Montgomery AB. Inhaled azteronam lysine for chronic airway Pseudomonas
aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921–8.
26. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS,
Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for
airway pseudomonas in cystic fibrosis. Chest. 2009;135:1223–32.
27. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS,
Montgomery AB, et al. An 18-month study of the safety and efficacy
of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
Pediatr Pulmonol. 2010;45:1121–34.
28. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC.
Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
N Engl J Med. 2006;354:241–50.
29. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA,
et al. Azithromycin in patients with cystic fibrosis chronically infected with
Pseudomonas aeruginosa: a randomized controlled trial. JAMA.
2003;290:1749–56.
30. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, et al. Inhaled
dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Eur Respir J. 2011;28:1071–80.
31. McKone E, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al.
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who
have the G551D-CFTR mutation: Response through 144 weeks of treatment
(96 weeks of PERSIST). Pediatr Pulmonol. 2013;48 Suppl 36:287.
32. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al.
Clinical mechanism of the cystic fibrosis transmembrane conductance
regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J
Respir Crit Care Med. 2014;190:175–84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Quittner et al. Health and Quality of Life Outcomes  (2015) 13:93 Page 9 of 9
